Investment Rating - The report maintains a "Buy" rating for Yidu Technology (2158.HK) [4] Core Insights - Yidu Technology has made significant advancements in AI medical innovation, including deep involvement in the National AI Application Pilot Base in Beijing and winning a Phase III clinical research project [1][2] - The company has expanded its health management platform and solutions by launching "Hui Min Bao" insurance services in Hebei and Guangzhou, enhancing its service reach [3] - Revenue and profit forecasts have been adjusted downward due to slower-than-expected progress in the AI digital therapy business, but the long-term market share is expected to improve [4] Summary by Sections AI Medical Innovation - Yidu Technology is a core partner in the National AI Application Pilot Base in Beijing, focusing on building a "data-algorithm-scenario" closed-loop for AI medical innovation [1] - The company has developed AI recruitment agents to improve clinical trial participant recruitment efficiency, successfully implemented in six projects [1] Clinical Research Projects - The company won a Phase III clinical research project for SMR001 eye drops, valued at approximately RMB 55.82 million, which is expected to enhance its market share in the long term [2] Health Management Solutions - The launch of "Hui Min Bao" in Hebei and Guangzhou has attracted over 200,000 participants on the first day, with the company serving over 40 million users across multiple provinces [3] Financial Forecasts - Revenue forecasts for FY2026 and FY2027 have been reduced by 19.4% and 24.9% to RMB 797 million and RMB 896 million, respectively, while FY2028 revenue is projected at RMB 1.007 billion [4][5] - The net profit forecast for FY2026 and FY2027 has been adjusted to -RMB 85 million and -RMB 36 million, with a positive net profit of RMB 8 million expected in FY2028 [4][5]

Core Viewpoint - The article discusses the challenges and potential of AI in healthcare, emphasizing that while AI shows promise in controlled environments, its integration into real clinical settings faces significant hurdles [1][2][4]. Group 1: AI Performance and Clinical Integration - Microsoft's AI diagnostic system scored four times higher than human doctors in a complex case test, highlighting AI's potential in medical diagnostics [1]. - A study from Harvard indicates that simply providing doctors with AI tools like ChatGPT does not improve diagnostic outcomes; optimal results occur when AI analyzes cases first, followed by human input [4]. - The disconnect between AI's technical capabilities and clinical needs is a core issue, as medicine requires both scientific and artistic approaches, which AI struggles to replicate [5]. Group 2: Challenges in Implementation - The integration of AI into clinical workflows is hindered by established practices among doctors, who may find AI tools burdensome rather than helpful [6]. - Medical data infrastructure is crucial for AI's effectiveness; for instance, Yidu Tech invested over $100 million over four years to build a data foundation necessary for AI applications [6]. - Patient trust remains paramount, as evidenced by a survey where none of the 3,000 patients chose hospitals based on AI tools, indicating that patients prefer human doctors over algorithms [6]. Group 3: Democratization of Healthcare - AI's ultimate goal is to democratize access to quality healthcare, as illustrated by a new insurance model in Beijing and Shenzhen that offers affordable premiums and high coverage [7]. - The use of AI in non-critical care settings is being explored to enhance service delivery, particularly in underserved areas [7]. - AI can reduce administrative burdens on doctors, allowing them to spend more time with patients, thus improving overall healthcare delivery [7]. Group 4: Future Collaboration Between Doctors and AI - There is a consensus that AI will not replace doctors; however, those who do not learn to utilize AI effectively may be outpaced by their peers [8]. - Medical education is evolving to include AI collaboration skills, ensuring future doctors can use AI tools while understanding their limitations [9]. - Continuous monitoring and optimization of AI tools are necessary to ensure they are user-friendly and effective for busy healthcare professionals [9].

Core Insights - The three principles proposed by the founder of Yidu Technology, Ms. Gong Rujing, emphasize that AI should not replace doctors, should remain contextually relevant, and should not abandon inclusivity in healthcare [1][9] - The forum held in Kuala Lumpur gathered global investment leaders and industry experts to discuss the future of AI in healthcare [1] Group 1: AI in Healthcare - Ms. Gong Rujing highlighted that there is no "universal AI," but rather precise solutions that fit into workflows, emphasizing the need for high-quality medical data and seamless integration into the entire diagnostic and treatment process [3][4] - Yidu Technology's "AI Medical Brain" YiduCore has processed over 6 billion medical records, establishing a robust foundation for AI applications in healthcare [4] - The company has developed over 1,000 intelligent agents covering various clinical needs, significantly improving efficiency and standardization in areas like oncology [4][6] Group 2: Inclusivity in Healthcare - The ultimate mission of AI in healthcare is to provide accessible and affordable health services to everyone, as stated by Ms. Gong Rujing [6] - Yidu Technology has participated in the development of health insurance projects across multiple provinces, offering insurance products with annual premiums as low as 100 yuan, benefiting millions [6][7] - The company has served over 40 million insured users, demonstrating the social equity driven by technology [6] Group 3: Globalization and Localization - Ms. Gong Rujing emphasized that globalization in AI healthcare should not be a mere replication of solutions but should involve "technology generalization + local adaptation" to create value with local partners [8] - Yidu Technology has implemented localized projects, such as the BruHealth digital health platform in Brunei, covering over 60% of the population [8] - The company is also involved in Singapore's "MIC@Home" project, supporting remote monitoring and management of discharged patients [8]

Core Viewpoint - The company, Yidu Tech (02158.HK), announced that it will hold a board meeting on November 27, 2025, to consider and approve its unaudited consolidated interim results for the six months ending September 30, 2025, and to discuss the potential declaration of an interim dividend, if any [1] Summary by Relevant Sections - **Company Announcement** - Yidu Tech will conduct a board meeting on November 27, 2025 [1] - The meeting will focus on the unaudited consolidated interim results for the six months ending September 30, 2025 [1] - The board will also consider the declaration of an interim dividend [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 醫渡科技有限公司 執行董事兼董事長 宮盈盈 香港，2025年11月17日 於本公告日期，執行董事為宮盈盈女士、徐濟銘先生、封曉瑛女士及謝麗博士；非執行董事為曾鳴先生；及獨立非執行 董事為馬維英博士、潘蓉容女士及張林琦教授。 Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) 董事會會議通告 醫渡科技有限公司（「本公司」，連同其附屬公司及其綜合聯屬實體，統稱為「本集團」）董事 （「董事」）會（「董事會」）謹此宣佈，本公司將於2025年11月27日（星期四）舉行董事會會議，藉 以（其中包括）考慮及批准本集團截至2025年9月30日止六個月之未經審核合併中期業績及其 發佈以及考慮派發中期股息（如有）。 ...

Core Insights - The 2025 Fortune Innovation Forum will be held in Kuala Lumpur, Malaysia, on November 17-18, gathering over 300 global business leaders, investment elites, and policymakers to explore new strategic paradigms in a rapidly changing world [2][5]. Group 1: Key Themes - The forum will address geopolitical tensions, protectionism, and the rapid evolution of artificial intelligence, which are reshaping traditional alliances and market foundations [2]. - The theme "Navigating Change: Winning Strategies in a Post-Globalized World" will focus on creating new opportunities in areas such as energy transition, sustainable development, and food security [2]. - Discussions will include the impact of technological advancements, digital revolutions, and artificial intelligence on business practices and workforce dynamics [4]. Group 2: Future Outlook - Malaysia's Johor state is projected to become a major data center hub in the next five years, potentially surpassing Northern Virginia in the U.S. [5]. - The forum aims to highlight Malaysia's growth story and unique strategic opportunities, positioning it as a focal point for global attention [5].

Group 1 - The core viewpoint of the news highlights the successful launch of the "Beijing Universal Health Insurance" project, which gained significant attention from the public, achieving over 2 million participants within just 10 days of its launch in 2026 [1] - Yidu Technology (医渡科技) has been providing comprehensive technical support and operational services for the "Beijing Universal Health Insurance" for five consecutive years, contributing to the development of a multi-tiered medical security system in the capital [1] - The project requires a robust operational platform with capabilities in product design, system platform construction, marketing, customer service, and claims processing, emphasizing the need for strong technological capabilities [1] Group 2 - Yidu Technology utilizes its "Medical Intelligent Brain" YiduCore to create intelligent models and manage risk prediction for large populations, offering a one-stop solution for product design, system construction, platform operation, marketing, customer service, and claims processing [1] - The company has participated in the development and operation of health insurance projects in 5 provinces and 13 cities, including Beijing, Shenzhen, and Hebei [1] Group 3 - Market sentiment reflects confidence in Yidu Technology's growth prospects, as evidenced by significant net purchases from southbound funds, totaling 102.6 million shares on November 11 [2] - As of November 11, southbound funds held a total of 249 million shares of Yidu Technology, with a cumulative market value of 1.376 billion HKD, representing a holding ratio of 23.27% [2]

Core Insights - The National Healthcare Security Administration's Big Data Center announced the list of project undertakers for 2025, with Yidu Technology winning two projects related to AI-assisted classification of medical consumables and the construction of disease archives [1][2] - The projects align with the recent implementation opinions from the National Health Commission and other departments, emphasizing the integration of healthcare, medical insurance, and pharmaceuticals, showcasing the company's strong application capabilities in this field [1][2] Group 1 - The two awarded projects focus on "intelligent classification of medical consumables" and "standardization of disease archives," which are critical issues in current medical insurance reforms and data application [1] - The implementation opinions highlight the need to enrich medical data supply, promote collaboration among healthcare sectors, and enhance data sharing and compliance [1] Group 2 - Yidu Technology has over ten years of experience in medical big data and AI, having processed more than 6 billion medical records and covering over 4,000 medical institutions nationwide, impacting 1.15 billion patients [2] - The company's systematic capabilities support the collaboration of healthcare sectors and data interconnectivity, reflecting its excellence in data governance, modeling methodologies, and AI application [2] - Yidu Technology aims to deepen its focus on medical insurance big data, real-world research, and AI, driving the transformation of innovative results into practical applications for a new model of efficient and intelligent medical insurance governance [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 醫渡科技有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 本月底法 ...

Investment Rating - The report recommends a "First Time Buy" rating for the AI healthcare industry [6] Core Insights - The AI healthcare industry is experiencing robust growth, with the market size in China expected to increase from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, representing a compound annual growth rate (CAGR) of 10.5% from 2022 to 2028 [2][28] - The industry is supported by various government policies aimed at accelerating the implementation of AI technologies in healthcare settings [3][37] - Different application scenarios within AI healthcare exhibit varying levels of maturity, with medical imaging and drug development showing rapid growth [4][32] Summary by Sections 1. AI Technology Development in Healthcare - AI healthcare refers to the use of advanced technologies such as machine learning, natural language processing, and computer vision to analyze complex medical data, assisting clinical decision-making and optimizing treatment processes [12] - The core technologies in AI healthcare include medical imaging analysis, natural language processing, drug development, and intelligent health management [14][18] 2. Market Size and Growth - The AI healthcare market in China was valued at 97.3 billion yuan in 2023 and is projected to reach 159.8 billion yuan by 2028, with a CAGR of 10.5% [28] - The AI medical imaging market is expected to grow significantly, with a projected size of approximately 74.5 billion yuan in 2024, reflecting a year-on-year growth of 160.5% [32] - The AI drug development market is anticipated to grow from 410 million yuan in 2023 to 5.86 billion yuan by 2028, with a CAGR of 68.5% [33] 3. Policy Support - The Chinese government has introduced multiple policies to support the development of AI in healthcare, including guidelines for AI applications in medical institutions [3][37] - Key policies include the "Artificial Intelligence + Action Plan" and the "Guidelines for the Pricing of AI-Assisted Diagnostic Services" [37] 4. Application Scenarios - AI healthcare applications can be categorized into pre-treatment, during treatment, and post-treatment stages, covering health promotion, disease prevention, diagnosis, treatment, rehabilitation, and chronic disease management [15][19] - The maturity of AI applications varies significantly across different scenarios, with medical imaging analysis being one of the most mature areas [22][24] 5. Key Companies in the Industry - **Weining Health**: Focuses on providing integrated solutions for healthcare information systems and has developed a medical AI model, WiNGPT, enhancing its service capabilities [50][51] - **Chuangye Huikang**: Specializes in healthcare information technology and has developed a comprehensive solution system for clinical decision support and electronic medical records [54][55] - **Yidu Technology**: Offers an AI-driven platform, YiduCore, that supports various healthcare sectors, including public health and clinical research [60][61] - **Donghua Software**: Develops AI solutions for healthcare, focusing on intelligent decision support systems and electronic medical record generation [65][66]